CRISPR/Cas9 therapeutics: progress and prospects
T Li, Y Yang, H Qi, W Cui, L Zhang, X Fu, X He… - … and Targeted Therapy, 2023 - nature.com
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated
protein 9 (Cas9) gene-editing technology is the ideal tool of the future for treating diseases …
protein 9 (Cas9) gene-editing technology is the ideal tool of the future for treating diseases …
Targeting biomolecular condensation and protein aggregation against cancer
Biomolecular condensates, membrane-less entities arising from liquid–liquid phase
separation, hold dichotomous roles in health and disease. Alongside their physiological …
separation, hold dichotomous roles in health and disease. Alongside their physiological …
Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy
Initiation and development of cancer depend on multiple factors that mutations in genes and
epigenetic level can be considered as important drivers. Epigenetic factors include a large …
epigenetic level can be considered as important drivers. Epigenetic factors include a large …
A study of miRNAs as cornerstone in lung cancer pathogenesis and therapeutic resistance: A focus on signaling pathways interplay
Lung cancer (LC) is the most common cancer-related death globally, and many efforts have
been made to improve the patient care of LC patients, as well as the development of efficient …
been made to improve the patient care of LC patients, as well as the development of efficient …
[HTML][HTML] Cell membrane-coated nanomaterials for cancer therapy
S Zeng, Q Tang, M **ao, X Tong, T Yang, D Yin, L Lei… - Materials Today Bio, 2023 - Elsevier
With the development of nanotechnology, nanoparticles have emerged as a delivery carrier
for tumor drug therapy, which can improve the therapeutic effect by increasing the stability …
for tumor drug therapy, which can improve the therapeutic effect by increasing the stability …
Drugs targeting p53 mutations with FDA approval and in clinical trials
Simple Summary Mutations in the tumor suppressor p53 (p53) occur in~ 50% of human
cancers, the majority of which are missense mutations. Mutations in p53 not only impair the …
cancers, the majority of which are missense mutations. Mutations in p53 not only impair the …
Small cell lung cancer transformation: From pathogenesis to treatment
X Yin, Y Li, H Wang, T Jia, E Wang, Y Luo, Y Wei… - seminars in Cancer …, 2022 - Elsevier
Small cell lung cancer (SCLC) is a type of neuroendocrine tumor with high malignancy and
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …
The potential role of miRNAs in the pathogenesis of testicular germ cell tumors-A Focus on signaling pathways interplay
Testicular germ cell tumors (TGCTs) are the most common testicular neoplasms in
adolescents and young males. Understanding the genetic basis of TGCTs represents a …
adolescents and young males. Understanding the genetic basis of TGCTs represents a …
Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies
Simple Summary Reprogramming of glucose metabolism is a hallmark of cancer and can be
targeted by therapeutic agents. Some metabolism regulators, such as ivosidenib and …
targeted by therapeutic agents. Some metabolism regulators, such as ivosidenib and …
[HTML][HTML] PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Abstract Mouse double minute 2 (MDM2) is an E3 ubiquitin ligase which effectively
degrades tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt …
degrades tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt …